IV thyroxin
ApprovedSmall molecule
IV thyroxin is one of 41 small molecule programs targeting Heart Failure. It is currently in Approved.
2
Indications
5
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1IV thyroxin
RRambam Health Care Campus
Approved
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Aciphex
Akero TherapeuticsPreclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure2 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IV thyroxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RRambam Health Care Campus